The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies

// Tingting Men 1, * , Cuicui Yu 2, * , Dan Wang 3 , Fang Liu 3 , Jingjing Li 3 , Xiaoying Qi 3 , Chunhua Yang 3 , Wenguo Jiang 3 , Xiaodan Wei 3 , Xuri Li 3 , Bin Wang 4 , Jia Mi 3 and Geng Tian 3 1 School of Nursing, Binzhou Medical University, Yantai, Shandong, China 2 Department of Anesthesiology, Yantai Yu Huang Ding Hospital, Yantai, Shandong, China 3 Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai, Shandong, China 4 Institute of Molecular Imaging, Binzhou Medical University, Yantai, Shandong, China * These authors have contributed equally to this work Correspondence to: Geng Tian, email: tiangengshandong@yeah.net Jia Mi, email: Jia.mi@kemi.uu.se Bin Wang, email: binwang001@aliyun.com Keywords: prostate cancer, interleukin-10, polymorphism, peripheral blood interleukin-10, meta-analysis Received: December 16, 2016      Accepted: April 11, 2017      Published: April 29, 2017 ABSTRACT This study purported to investigate the impact of interleukin-10 (IL-10) gene 4 polymorphisms (-1082G>A, -819T>C, -592A>C and 210T>C) on peripheral blood IL-10 variation and prostate cancer (PCa) risk, with a special consideration given to various origins of between-study heterogeneity. 2 researchers independently fulfilled literature retrieval, quality assessment and information collection. Sub-grouped analyses per ethnicity, continent, design type, control source, genotyping procedure, genotype validation, age-matched status, study sample size, quality score and controls’ mean age were conducted, respectively. Total 17 unduplicated studies (patients/controls: 7561/8101) were assessable for PCa risk, and 4 unduplicated studies (1189 subjects) for peripheral blood IL-10 variation. Pooling all assessable studies identified a marginally significant association between the -1082A allele and increased PCa risk (odds ratio (OR)=1.10, 95% confidence interval [CI]: 1.00 to 1.21) (Heterogeneity I 2 =64.3%), and no significance was detected in sub-grouped analyses of this polymorphism. Contrastingly, the -592C allele was significantly associated with reduced PCa risk in both prospective (OR=0.85, 95% CI: 0.77 to 0.95) and population-based (OR=0.92, 95% CI: 0.84 to 1.00) studies (Heterogeneity I 2 =0.0% and 18.1%). Moreover, carriers of combined -592CA/CC genotypes had a significant higher level of peripheral blood IL-10 than the -592AA genotype carriers (weighted mean difference=0.45 and 0.54 mg/dL, 95% CI: 0.23 to 0.67 and 0.30 to 0.39). The above comparisons possessed a low probability of publication bias. In sum, our findings suggested that IL-10 gene -592A>C polymorphism may represent a promising candidate locus for the occurrence of PCa, and further signified a contributing role of this polymorphism in prostate carcinogenesis.